MARKET

SAGE

SAGE

SAGE
NASDAQ

Real-time Quotes | Nasdaq Last Sale

37.67
-1.39
-3.56%
After Hours: 38.00 +0.33 +0.88% 17:54 05/27 EDT
OPEN
39.54
PREV CLOSE
39.06
HIGH
39.82
LOW
36.66
VOLUME
873.08K
TURNOVER
--
52 WEEK HIGH
193.56
52 WEEK LOW
25.01
MARKET CAP
1.96B
P/E (TTM)
-3.0240
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 22 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average SAGE stock price target is 73.88 with a high estimate of 190.00 and a low estimate of 35.00.

EPS

SAGE News

More
Is Axsome Therapeutics a Buy?
MotleyFool.com · 1d ago
RBC Capital Reiterates Outperform on Sage Therapeutics, Raises Price Target to $75
RBC Capital reiterates Sage Therapeutics (NASDAQ:SAGE) with a Outperform and raises the price target from $72 to $75.
Benzinga · 1d ago
Axsome Therapeutics: Sliding Share Price And FDA Approvals Highlight Gains
Seeking Alpha - Article · 5d ago
Sage Therapeutics Inc (SAGE) Q1 2020 Earnings Call Transcript
MotleyFool.com · 05/09 04:00
Benzinga's Top Upgrades, Downgrades For May 8, 2020
Upgrades
Benzinga · 05/08 19:03
Wedbush Downgrades Sage Therapeutics to Neutral, Raises Price Target of $37
Wedbush analyst Laura Chico downgrades Sage Therapeutics (NASDAQ:SAGE) from Outperform to Neutral and raises the price target from $36 to $37.
Benzinga · 05/08 17:13
SunTrust Robinson Humphrey Maintains Hold on Sage Therapeutics, Lowers Price Target to $35
SunTrust Robinson Humphrey maintains Sage Therapeutics (NASDAQ:SAGE) with a Hold and lowers the price target from $37 to $35.
Benzinga · 05/08 15:26
RBC Capital Maintains Outperform on Sage Therapeutics, Raises Price Target to $72
RBC Capital maintains Sage Therapeutics (NASDAQ:SAGE) with a Outperform and raises the price target from $71 to $72.
Benzinga · 05/08 13:39

Industry

Biotechnology & Medical Research
+0.53%
Pharmaceuticals & Medical Research
+0.23%

Hot Stocks

Symbol
Price
%Change

About SAGE

SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company's lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor. The Company's next-generation product candidates, SAGE-217 and SAGE-689, also target the GABAA receptor system. The Company is focused on developing drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors. The Company's chemistry platform is focused on the chemical scaffolds of endogenous or chemically modified synthetic neuroactive steroid compounds that are allosteric modulators of GABAA or N-Methyl-D-aspartic acid or N-Methyl-D-aspartate (NMDA) receptors.
More

Webull offers kinds of SAGE Therapeutics Inc stock information, including NASDAQ:SAGE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SAGE stock news, and many more online research tools to help you make informed decisions.